2076975 2077203
최종편집 2024-06-15 22:14 (토)
Sales of Chung Sim WonㆍWhal Myung SuㆍGelfosㆍAntiphlamine boom amid COVID-19
상태바
Sales of Chung Sim WonㆍWhal Myung SuㆍGelfosㆍAntiphlamine boom amid COVID-19
  • Hyeokgi Lee, Newsmp
  • 승인 2021.12.14 15:37
  • 댓글 0
이 기사를 공유합니다

Kwang Dong Pharmaceutical Chung Sim Won preparations KRW 40 billion, Yuhan     Corporation Antiphlamine close to KRW 20 billion
Boryung Pharmaceutical GelfosㆍDong Wha Pharm Whal Myung Su preparations grew     around 9%

While the spread of COVID-19 has not subsided, major listed pharmaceutical companies’ flagship nonprescription products are booming.

Yuhan Corporation’s Antiphlamine sales surged by nearly 20% in the third quarter to KRW 17.1 billion, reaching KRW 20 billion. Mag-B’s sales also grew 9.3% over the same period, approaching the KRW 10 billion mark.

Chung Sim Won is also showing strength. Kwang Dong Pharmaceutical’s sales in Chung Sim Won-related amounted to KRW 38.1 billion, up KRW 4.6 billion, or 13.6% year-on-year.

Although it is smaller than Kwang Dong Pharmaceutical, Samsung Pharmaceutical’s Woo Whang Chung Sim Won’s sales also soared 44.4% year-on-year to KRW 1.7 billion.


Whal Myung Su of Dong Wha Pharm, which surpassed KRW 50 billion in three quarters of last year, expanded 8.7% this year to KRW 54.7 billion.

While the sales of Fucidin and Pancold dropped nearly 10% as the respiratory disease treatment market shrank and outdoor activities decreased due to the daily use of masks, Itchi rose 10.4% year-on-year to KRW 18.3 billion, approaching the KRW 20 billion mark.

The growth of vitamin-related products appears to slow down. Il Dong Pharmaceutical’s Aronamin, Exeramin, and Daewoong Pharmaceutical’s Impactamin left poor performance than the same period last year.

Yuhan recorded nearly double-digit growth in Mag-B, but sales of Vitamin C Tab. 1000mg decreased from a year earlier, and Megatrue’s growth remained at 1.0%.

Kwang Dong Pharmaceutical’s Vita 500 saw a slight decrease in pharmacy sales, but the overall sales volume increased slightly as sales in the distribution sector rose a bit.

Moreover, Daewoong Pharmaceutical’s Ursa recorded KRW 64.4 billion in combined sales of over the counter (OTC) and ethical the counter (ETC), a slight increase from the same period last year.
 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.